Literature DB >> 22307917

Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma.

Yan Zhao, Man Yang, Xingshun Qi, Guohong Han, Daiming Fan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22307917     DOI： 10.1002/hep.25639

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  4 in total

Review 1.  Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Alessandro Granito; Sara Marinelli; Giulia Negrini; Saverio Menetti; Francesca Benevento; Luigi Bolondi
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 2.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

Review 3.  Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Man Yang; Jin-Qiu Yuan; Ming Bai; Guo-Hong Han
Journal:  Mol Biol Rep       Date:  2014-08-05       Impact factor: 2.316

4.  Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma.

Authors:  Shunsuke Nojiri; Atsunori Kusakabe; Kei Fujiwara; Noboru Shinkai; Kentaro Matsuura; Etsuko Iio; Tomokatsu Miyaki; Tomoyuki Nomura; Satoshi Sobue; Hitoshi Sano; Izumi Hasegawa; Tomoyoshi Ohno; Yoshitsugu Takahashi; Etsuro Orito; Takashi Joh
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.